by Bill Sardi, Lew Rockwell:

Coronacvirus Vaccination Catastrophe in The Making

ANSWERS TO 23 KEY QUESTIONS ABOUT COVID-19 VACCINES

An army larger than any in the world is about to fight a common enemy – COVID-19 coronavirus.  The nations of the world will be singularly devoted to achieve one objective: halt the spread and mortality emanating from a lung infection caused by a mutated coronavirus.

Operation Warp Speed aims to deliver millions of doses of a COVID-19 coronavirus vaccine by January, 2021.  United Parcel Service is building “freezer farms,” refrigerated storehouses to hold vaccines and is preparing for home delivery of vaccines and a team of nurses to immunize locked-down populations.  Billions of dollars of vaccines have been pre-ordered on the presumption a vaccine will pass Stage 3, achieve FDA licensure and enter into common use (Stage 4).

Vaccines intended for COVID-19 prevention need to enroll 3000 participants and show they are relatively safe, preferably compared to a placebo, among young healthy adults and elderly populations.  (FDA Guidance page 15).  According to the CDC, Phase 3 trials typically last several years.  So, shortcuts are being taken.  A recent poll finds 69% of Americans worry that  fast-tracked COVID-19 vaccines won’t be safe.

Live Science reports that Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said in April 2020 that a promising COVID-19 vaccine that produces a strong immune response in Phase 2 trials could potentially be approved for emergency use without a full Phase 3 trial.

The vaccine industry suggests a vaccine may gain early FDA licensure by a process called “immune correlation” – show the vaccine produces levels of neutralizing antibodies in the blood that are at least as high as patients naturally infected by the virus.  A problem that has only recently been recognized is that zinc-dependent T-cells, not antibodies, are killing off COVID-19 infected cells.  Antibody testing as a measure of vaccine effectiveness may be incomplete or even entirely misleading.

Question: How well does a vaccine have to perform to gain FDA licensure?

Answer: The FDA has set a low bar for licensure of COVID-19 vaccines.  Their guidance document (page 14) states: “a vaccine should show at least 50% efficacy in clinical trials, meaning that under perfect conditions, people who get the vaccine would be at least half as less likely to be infected with the coronavirus compared with unvaccinated people.”  So, it’s a coin flip whether vaccinated individual would benefit from vaccination given the everyone is at immediate risk for infection.

The insanity of all of this is that if a person’s lungs become infected with COVID-19 coronavirus and they test positive for the virus, they can be forced into quarantine in some locales.  But if you are inoculated and then test positive (yes, vaccines, except RNA and DNA vaccines, ARE the virus), then what?

Viral shedding from natural COVID-19 infection ranges from 8-37 days!  Given it is anticipated repeat inoculations will be required to achieve immunity, there is concern over a study which shows repeated flu vaccine recipients shed 6.3 times more viral particles into the air than non-vaccinated individuals.  Among individuals who don’t want to vaccinate, 4 in 10 say they are concerned about catching COVID-19 from the shot.

The world will not likely discover the number of side effects that occur until a vaccine gains licensure and widespread immunization begins (Phase 4).  At that point, the whole world is enrolled in one big clinical study using a variety of vaccines.  It’s entirely possible that mass vaccination may be more deadly than the disease itself, not necessarily due to vaccine toxicity but because of the frailty of older-age populations that cannot endure the rigors of hospitalization.

So far, eight months into this epidemic (Aug. 13), 749,000 people have reportedly died worldwide with COVID-19 (that is 0.000096% or 9.6 deaths per 100,000), but more than 80% had pre-existing co-morbid conditions.  So maybe only ~150,000 have died of COVID-19 alone (0.000019% or 19 per 100,000).

There is only a remote chance of dying solely from COVID-19 and 5263 people have to be vaccinated to prevent 1 death.  A vaccine that is only 50% effective would require double that number of vaccinated subjects to avert 1 COVID-19-related death.  The vaccine can be no more effective than the death rate.  Overvaccination would be the rule.

Read More @ LewRockwell.com